Last update 01 Nov 2024

ER x CDK4 x CDK6 x aromatase

Basic Info

Related Targets
ERCDK4CDK6[+1]

Related

1
Drugs associated with ER x CDK4 x CDK6 x aromatase
Letrozole/Ribociclib Succinate
Target
CDK4 x CDK6 x ER x aromatase
Mechanism
CDK4 inhibitors [+3]
Active Org.
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
Originator Org.
Novartis Pharma AG
Active Indication
Hormone receptor positive HER2 negative breast cancer
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date04 May 2017
1
Clinical Trials associated with ER x CDK4 x CDK6 x aromatase
NCT03283384 / Active, not recruitingPhase 2IIT
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
100 Clinical Results associated with ER x CDK4 x CDK6 x aromatase
Login to view more data
100 Translational Medicine associated with ER x CDK4 x CDK6 x aromatase
Login to view more data
0 Patents (Medical) associated with ER x CDK4 x CDK6 x aromatase
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free